Experts Warn Against Pharma Influence in Obesity Destigmatization Campaigns
By Rachel Kim

Experts have raised concerns about pharmaceutical companies' campaigns to destigmatize obesity, warning that these efforts might unduly influence public discourse and national health policy. According to a report in The BMJ, while reducing stigma around obesity is important, the involvement of companies profiting from obesity treatments could skew the conversation towards pharmaceutical solutions.
Michael Viggars and colleagues argue that such campaigns risk prioritizing drug treatments over addressing the systemic and structural causes of obesity. This concern is echoed in a recent article from STAT, which criticized Eli Lilly's "Obesity is a Sick Thing" campaign for implying that pharmacological treatments are the primary solution, potentially overshadowing non-drug approaches.
Further complicating the issue, a multimillion-pound NHS obesity-services programme, partly funded by Eli Lilly, has been criticized for potential conflicts of interest. The programme, which received £35 million from Eli Lilly out of a total £85 million, aims to expand weight-management services but has been described by some experts as "marketing by another name."
Additionally, Novo Nordisk has invested heavily in promoting obesity as a medical condition requiring long-term pharmaceutical intervention. This strategic move, outlined as early as 2015, aims to create legitimacy and urgency around treating obesity with drugs.
Researchers in the JAMA Health Forum highlight the importance of focusing on upstream sociopolitical drivers of obesity, such as sugar taxes and restrictions on ultraprocessed food marketing, as effective public health tools. They argue that framing obesity solely as an individual biomedical issue amplifies corporate influence and detracts from these systemic policies.